Quick Takeaways
- CITADEL ADVISORS LLC filed SCHEDULE 13G for Aardvark Therapeutics, Inc. Common Stock, par value $0.00001 per share (the "Shares").
- Disclosed ownership: 5.6%.
- Date of event: 14 Feb 2025.
Quoteable Key Fact
"CITADEL ADVISORS LLC disclosed 5.6% ownership in Aardvark Therapeutics, Inc. Common Stock, par value $0.00001 per share (the "Shares") on 14 Feb 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Citadel Advisors LLC | 5.4% | 1,152,375 | 0 | 1,152,375 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Advisors Holdings LP | 5.4% | 1,152,375 | 0 | 1,152,375 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel GP LLC | 5.4% | 1,152,375 | 0 | 1,152,375 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities LLC | 0.2% | 40,596 | 0 | 40,596 | /s/ Guy Miller | Guy Miller, Authorized Signatory | |
| Citadel Securities Group LP | 0.2% | 40,596 | 0 | 40,596 | /s/ Guy Miller | Guy Miller, Authorized Signatory | |
| Citadel Securities GP LLC | 0.2% | 40,596 | 0 | 40,596 | /s/ Guy Miller | Guy Miller, Authorized Signatory | |
| Kenneth Griffin | 5.6% | 1,192,971 | 0 | 1,192,971 | /s/ Seth Levy | Seth Levy, attorney-in-fact* |